Cynata Therapeutics Limited
Cynata Therapeutics Limited (CYYNF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cyynf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 4 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cynata Therapeutics LimitedYou CYYNF | $37M | N/A | — | -$0.04 |
 The Cannabist Company Holdings Inc. CBSTF | $14M | N/A | — | -$0.23 |
 Drug Free Solution, Inc. DSOL | $0M | N/A | — | -$0.00 |
 Medical Developments International Limited MDDVF | $34M | 608.90x | — | $0.00 |
 Novacyt S.A. NVYTF | $35M | N/A | — | -$0.33 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cynata Therapeutics Limited (CYYNF) measures how much investors pay for each dollar of the company's trailing earnings. CYYNF's current PE ratio of N/A is calculated by dividing its stock price of $0.15 by its TTM earnings per share of -$0.04.
Frequently asked questions
CYYNF pe ratio · 6 questionsCYYNF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.15 and TTM EPS of -$0.04. Data sourced from Financial Modeling Prep via CYYNF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cynata Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09